Patents by Inventor Kenneth James Miller, II

Kenneth James Miller, II has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9492401
    Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.
    Type: Grant
    Filed: December 27, 2010
    Date of Patent: November 15, 2016
    Assignee: Mylan Technologies, Inc.
    Inventors: Kristin Jackson, Kenneth James Miller, II
  • Patent number: 8614274
    Abstract: A medical grade adhesive comprises a mixture of at least one cross-linkable pressure sensitive adhesive component and at least one non-cross-linkable pressure-sensitive adhesive component, wherein the amount of each of said components is such that the resultant adhesive can adhere to human skin for a period of up to about 7-10 days but can be removed without causing trauma to the skin.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: December 24, 2013
    Assignee: Mylan Technologies Inc.
    Inventors: Kristin Jackson, Kenneth James Miller, II
  • Publication number: 20110151003
    Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.
    Type: Application
    Filed: December 27, 2010
    Publication date: June 23, 2011
    Applicant: Mylan Technologies, Inc.
    Inventors: Kristin JACKSON, Kenneth James Miller, II
  • Publication number: 20110106022
    Abstract: A medical grade adhesive comprises a mixture of at least one cross-linkable pressure sensitive adhesive component and at least one non-cross-linkable pressure-sensitive adhesive component, wherein the amount of each of said components is such that the resultant adhesive can adhere to human skin for a period of up to about 7-10 days but can be removed without causing trauma to the skin.
    Type: Application
    Filed: January 11, 2011
    Publication date: May 5, 2011
    Applicant: Mylan Technologies Inc.
    Inventors: Kristin Jackson, Kenneth James Miller, II
  • Patent number: 7888422
    Abstract: A medical grade adhesive comprises a mixture of at least one cross-linkable pressure sensitive adhesive component and at least one non-cross-linkable pressure-sensitive adhesive component, wherein the amount of each of said components is such that the resultant adhesive can adhere to human skin for a period of up to about 7-10 days but can be removed without causing trauma to the skin.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: February 15, 2011
    Assignee: Mylan Technologies Inc.
    Inventors: Kristin Jackson, Kenneth James Miller, II
  • Publication number: 20080305155
    Abstract: A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.
    Type: Application
    Filed: March 28, 2008
    Publication date: December 11, 2008
    Applicant: MYLAN TECHNOLOGIES, INC.
    Inventors: Kristin Jackson, Kenneth James Miller, II